The timing hypothesis for coronary heart disease prevention with hormone therapy: Past, present and future in perspective

Climacteric

Volumn 15, Issue 3, 2012, Pages 217-228

  Hodis, H N ^a   Collins, P ^b   MacK, W J ^a   Schierbeck, L Lind ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CORONARY HEART DISEASE; ESTROGEN; HORMONE THERAPY; MENOPAUSE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIALS; TIMING HYPOTHESIS; WOMEN

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ATORVASTATIN; BETA CAROTENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FENOFIBRATE; GESTAGEN; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; ZOLEDRONIC ACID;

BRAIN HEMORRHAGE; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FEMALE; FEMUR SHAFT FRACTURE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG EMBOLISM; MENOPAUSE; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; RISK; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SUDDEN DEATH; VENOUS THROMBOEMBOLISM;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WOMEN'S HEALTH;

EID: 84861409481     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.656401     Document Type: Review

References (82)

1. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiol Dis 1995;38:199-210
2. Grodstein F, Stampfer M. Estrogen for women at varying risk of coronary disease. Maturitas 1998;30:19-26 (Pubitemid 29027811)
3. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Commun Health 1989;43:173-8 (Pubitemid 19147305)
4. Falkeborn M, Persson I, Adami HO. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8
5. Psaty BM, Heckbert SR, Atkins D, et al . The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154:1333-9 (Pubitemid 24197677)
6. Grodstein F, Stampfer MJ, Manson JE, et al . Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61 (Pubitemid 26269944)
7. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-14 (Pubitemid 41191425)
8. Prentice RL, Langer R, Stefanick ML, et al . Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone therapy and cardiovascular disease. Am J Epidemiol 2006;163:589-99
9. Henderson BD, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151:75-8
10. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41 (Pubitemid 32003509)
11. Hulley S, Grady D, Bush T, et al . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13 (Pubitemid 28502636)
12. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9 (Pubitemid 30650747)
13. Hodis HN, Mack WJ, Lobo RA , et al . Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53 (Pubitemid 33131615)
14. Hodis HN, Mack WJ, Azen SP, et al . Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45 (Pubitemid 36951365)
15. Hodis HN, Mack WJ. A window of opportunity: the reduction of coronary heart disease and total mortality with menopausal therapies is age and time dependent. Brain Res 2011;1379: 244-52
16. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009;207:336-40
17. NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefit. National Institutes of Health, NIH News Release; 9 July 2002. http://www.nhlbi.nih.gov/new//press/02-07-09.htm
18. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)
19. Writing Group for the Women' s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
20. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523-34 (Pubitemid 36951364)
21. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006;15:35-44 (Pubitemid 43192860)
22. The Women' s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
23. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65 (Pubitemid 43244325)
24. LaCroix AZ, Chlebowski RT, Manson JE, et al., for the WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
25. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. J Gen Intern Med 2006;21: 363-6
26. Manson JE, Allison MA, Rossouw JE, et al., for the WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-602 (Pubitemid 46961004)
27. Salpeter SR, Walsh JME, Greybe E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804 (Pubitemid 38951954)
28. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119: 922-30
29. Cummings SR, Ensrud K, Delmas PD, et al., for the PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
30. Hodis HN, Mack WJ, Kono N, et al., for the WISH Research Group. Isofl avone soy protein supplementation and progression of subclinical atherosclerosis in healthy postmenopausal women: a randomized controlled trial. Stroke 2011;42:3168-75
31. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;12:1016-22
32. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42-52
33. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243-52 (Pubitemid 38608174)
34. Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of gender in primary prevention of coronary heart disease with stain therapy: a meta-analysis. Int J Cardiol 2010;138:25-31
35. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
36. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304
37. Berger JS, Roncaglioni MC, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specificmeta-analysis of randomized controlled trials . JAMA 2006;295: 306-13
38. Ogawa H, Nakayama M, Morimoto T, et al . Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41
39. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069-77
40. de Lorgeril M, Salen P, Abramson J, et al . Cholesterol lowering, cardiovascular diseases, and rosuvastatin-JUPITER controversy. Arch Intern Med 2010;170:1032-6
41. Kaul S, Morrissey RP, Diamond GA. By jove! What is a clinician to make of JUPITER? Arch Intern Med 2010;170:1073-7
42. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
43. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93 (Pubitemid 38198877)
44. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol 2008; 51:564-80
45. Hodis HN, Mack WJ. Postmenopausal hormone therapy in clinical perspective. Menopause 2007;14:944-57 (Pubitemid 47517597)
46. Hodis HN. Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleveland Clin J Med 2008;75(Suppl 4):S3-12
47. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: a realistic perspective. Climacteric 2011;14:33-6
48. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55: 103-15 (Pubitemid 44307491)
49. Heiss G, Wallace R, Anderson GL, et al., for the WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299:1036-45
50. Stefanick ML, Anderson GL, Margolis KL, et al., for the WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
51. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9 (Pubitemid 34951488)
52. Simon JA, Hsia J, Cauley JA, et al., for the HERS Research Group. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42 (Pubitemid 32144190)
53. Wassertheil-Smoller S, Hendrix SL, et al., for the WHI Investi gators. Effect of estrogen plus progestin on stroke in post menopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84 (Pubitemid 37430138)
54. Cushman M, Kuller LH, Prentice R, et al., for the Women'sHealth Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis . JAMA 2004;292:1573-80 (Pubitemid 39314963)
55. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80
56. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80 (Pubitemid 43042692)
57. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies . J Clin Oncol 2005;23:8606-12 (Pubitemid 46211502)
58. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
59. Margolis KL, Bonds DE, Rodabough RJ, et al ., for the Women'sHealth Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative hormone trial. Diabetologia 2004;47:1175-87 (Pubitemid 39093314)
60. Kanaya AM, Herrington D, Vettinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/ progestin Replacement Study. Ann Intern Med 2003; 138:1-9
61. Bonds DE, Lasser N, Qi L, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomized trial. Diabetologia 2006;49:459-68 (Pubitemid 43277868)
62. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-42
63. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9
64. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64
65. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal woman in the Women'sHealth Initiative. Arch Intern Med 2012, Jan 9. Epub ahead of print
66. Nelson HD, Vesco KK, Haney E, et al. Nonhumoral therapies for menopausal hot fl ashes: systematic review and meta-analysis. JAMA 2006;295:2057-71 (Pubitemid 44794007)
67. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59
68. Collins R, Armitage J, Parish S, Sleight P, Peto R, for the Heart Protection Study Collaborative Group. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67
69. Shepherd J, Blauw GJ, Murphy MB, et al ., on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30 (Pubitemid 35379733)
70. The FIELD Study Investigators. Effects of long-term fenofi brate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial . Lancet 2005;366:1849-61
71. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet 2006;368:1096-105
72. Home PD, Pocock SJ, Beck-Nielsen H, et al ., for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009;373: 2125-35
73. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9
74. Dormandy J, Bhattacharya M, de Bruyn ART, on behalf of the PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Safety 2009;32: 187-202
75. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fi brillation in women. Arch Intern Med 2008;168:826-31 (Pubitemid 351649266)
76. Black DM, Delmas PD, Eastell R, et al., for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22 (Pubitemid 46698462)
77. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364;1728-37
78. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008;336:262-6 (Pubitemid 351251627)
79. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of acombination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5 (Pubitemid 26137973)
80. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians'Health Study. N Engl J Med 1989;321:129-35
81. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al . Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone . JAMA 2010;304:411-18
82. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691